Indivior shares slump 20% on reported loss

13 February 2020

UK drugmaker Indivior (LSE: INDV) lost 20% of its market value on Thursday after reporting a $46 million adjusted operating loss for the latest quarter.

The addiction specialist saw its profits plummet during the quarter, having reported a $78 million gain in the same period of 2018, as sales of its Suboxone (buprenorphine and naloxone) Film treatment fell away due to generic competition. Over 2019 as a whole, the company earned $202 million, a 39% drop on the previous year.

Indivior’s net revenue for the fourth quarter of 2019 was $133 million, a 44% decline on the $236 million of a year earlier, while the sales figure for 2019 was $785 million, down 22%.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK